1. Scrip
  2. >>Conferences
  3. >>ASCO

ASCO: Legend/J&J Explore Carvykti In Community

Data Show FHR Myeloma Efficacy

 
• By Alaric DeArment

The companies presented data from CARTITUDE-4 in functional high-risk disease, which has a poorer prognosis, while they are also piloting a program to expand Carvykti’s geographic reach.

Legend stand at ASCO 2024
• Source: Scrip

With a recent label expansion that quadruples the number of multiple myeloma patients eligible to receive the CAR-T cell therapy Carvykti (ciltacabtagene autoleucel), Legend Biotech Corp. and partner Johnson & Johnson are looking to expand the therapy’s availability beyond the tertiary care centers where it has long been confined.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from ASCO

TIL The CARs Come Home: How Cell Therapy’s Solid Tumor Future Is Shaping Up

 
• By Alaric DeArment

Iovance’s Amtagvi won FDA accelerated approval in February, and Adaptimmune’s afami-cel may not be far behind, but cell therapies for solid tumors come with some extra challenges.

Anti-TROP2 ADCs Lung Cancer Futures Likely Lie In Earlier-Stage Disease

 
• By Alaric DeArment

The discussant at ASCO’s NSCLC session said the field would need to “manage expectations” as the drugs do not appear to beat chemotherapy in all-comers. 

ASCO 2024 Wrap-Up Podcast

 
• By Alaric DeArment

Scrip reporter Alaric DeArment is joined by the Datamonitor Healthcare oncology analysts to review key highlights from the recent American Society of Clinical Oncology annual meeting.   

China Biotech Podcast: BIOSECURE Act Updates ASCO Highlights

 
• By Brian Yang and Dexter Jie Yan

US-based Citeline writer Sarah Karlin-Smith joins Brian Yang and Dexter Yan in China to discuss the US BIOSECURE Act and the recent BIO meeting in San Diego, while Dexter Yan discusses China-related ASCO highlights, in this mixed Chinese- and English-language episode.

More from Conferences